|
|
POLA1 |
DNA polymerase alpha 1, catalytic subunit |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Polymerase switching on the C-strand of the telomere
- Telomere C-strand synthesis initiation
- DNA replication initiation
- Activation of the pre-replicative complex
- Polymerase switching
- Removal of the Flap Intermediate
- Processive synthesis on the lagging strand
- G1/S-Specific Transcription
- Defective pyroptosis
|
- Cladribine
- Clofarabine
- Fludarabine
- Nelarabine
|
|
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Thyroid cancer
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Type II diabetes mellitus
|
|
|
PPIA |
peptidylprolyl isomerase A |
- Platelet degranulation
- Uncoating of the HIV Virion
- Budding and maturation of HIV virion
- Integration of provirus
- Early Phase of HIV Life Cycle
- Minus-strand DNA synthesis
- Plus-strand DNA synthesis
- Binding and entry of HIV virion
- Assembly Of The HIV Virion
- APOBEC3G mediated resistance to HIV-1 infection
- Calcineurin activates NFAT
- Basigin interactions
- Neutrophil degranulation
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- SARS-CoV-1 activates/modulates innate immune responses
|
- Cyclosporine
- Proline
- (3r)-1-Acetyl-3-Methylpiperidine
- Ethyl Oxo(Piperidin-1-Yl)Acetate
- Sanglifehrin A
- Copper
- Artenimol
|
|
|
|
PPP1CA |
protein phosphatase 1 catalytic subunit alpha |
- Triglyceride catabolism
- DARPP-32 events
- Downregulation of TGF-beta receptor signaling
- Maturation of hRSV A proteins
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
- 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
|
|
|
|
PPP1CB |
protein phosphatase 1 catalytic subunit beta |
- Triglyceride catabolism
- Downregulation of TGF-beta receptor signaling
- Regulation of PLK1 Activity at G2/M Transition
- RHO GTPases activate PKNs
- RHO GTPases activate PKNs
- RHO GTPases activate CIT
- RHO GTPases Activate ROCKs
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- RAF activation
- SHOC2 M1731 mutant abolishes MRAS complex function
- Gain-of-function MRAS complexes activate RAF signaling
- Maturation of hRSV A proteins
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
|
|
|
|
PPP1CC |
protein phosphatase 1 catalytic subunit gamma |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Triglyceride catabolism
- Downregulation of TGF-beta receptor signaling
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- RHO GTPases Activate Formins
- RAF activation
- Mitotic Prometaphase
- EML4 and NUDC in mitotic spindle formation
- SHOC2 M1731 mutant abolishes MRAS complex function
- Gain-of-function MRAS complexes activate RAF signaling
- Maturation of hRSV A proteins
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
- 9,10-Deepithio-9,10-Didehydroacanthifolicin
- Calyculin A
- Motuporin
|
|
|
|
PPP1R26 |
protein phosphatase 1 regulatory subunit 26 |
|
|
|
|
|
PPP1R9B |
protein phosphatase 1 regulatory subunit 9B |
|
|
|
|
|
PRDM2 |
PR/SET domain 2 |
|
|
|
|
|
PRKCB |
protein kinase C beta |
- Disinhibition of SNARE formation
- Activation of NF-kappaB in B cells
- Trafficking of GluR2-containing AMPA receptors
- G alpha (z) signalling events
- Depolymerization of the Nuclear Lamina
- WNT5A-dependent internalization of FZD4
- VEGFR2 mediated cell proliferation
- RHO GTPases Activate NADPH Oxidases
- Response to elevated platelet cytosolic Ca2+
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
|
- Vitamin E
- Tamoxifen
- Phosphorylcolamine
- Staurosporine
- Dequalinium
- Enzastaurin
- Ellagic acid
- Cholecystokinin
- Benzoyl peroxide
- alpha-Tocopherol succinate
- D-alpha-Tocopherol acetate
|
|
|
|
PRKRA |
protein activator of interferon induced protein kinase EIF2AK2 |
- MicroRNA (miRNA) biogenesis
- Small interfering RNA (siRNA) biogenesis
- PKR-mediated signaling
|
|
- Primary torsion dystonia (PTD)
|
|
|
PRMT2 |
protein arginine methyltransferase 2 |
|
|
|
|
|
PSMD10 |
proteasome 26S subunit, non-ATPase 10 |
- Proteasome assembly
- Proteasome assembly
|
|
|
|
|
PURA |
purine rich element binding protein A |
|
|
|
|
|
RABGAP1L |
RAB GTPase activating protein 1 like |
|
|
|
|
|
RACK1 |
receptor for activated C kinase 1 |
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- TNFR1-mediated ceramide production
- Degradation of CDH1
|
|
|
|
|
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
- Stimuli-sensing channels
- Rap1 signalling
- GP1b-IX-V activation signalling
- CD209 (DC-SIGN) signaling
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- SHOC2 M1731 mutant abolishes MRAS complex function
- Gain-of-function MRAS complexes activate RAF signaling
- IFNG signaling activates MAPKs
|
- Sorafenib
- LErafAON
- XL281
- iCo-007
- Cholecystokinin
- Regorafenib
- Dabrafenib
- Fostamatinib
|
|
|
|
RASA1 |
RAS p21 protein activator 1 |
- Downstream signal transduction
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- VEGFR2 mediated cell proliferation
- Regulation of RAS by GAPs
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
- RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
|
|
|
RBAK |
RB associated KRAB zinc finger |
|
|
|
|
|
RBBP4 |
RB binding protein 4, chromatin remodeling factor |
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- G0 and Early G1
- Polo-like kinase mediated events
- PRC2 methylates histones and DNA
- Oxidative Stress Induced Senescence
- HDACs deacetylate histones
- PKMTs methylate histone lysines
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Deposition of new CENPA-containing nucleosomes at the centromere
- Regulation of TP53 Activity through Acetylation
- Cyclin E associated events during G1/S transition
- G1/S-Specific Transcription
- Cyclin A:Cdk2-associated events at S phase entry
- RNA Polymerase I Transcription Initiation
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Transcriptional Regulation by E2F6
- HCMV Early Events
- Potential therapeutics for SARS
- Defective pyroptosis
- Negative Regulation of CDH1 Gene Transcription
- Regulation of endogenous retroelements by KRAB-ZFP proteins
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
- Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
- Regulation of PD-L1(CD274) transcription
|
|
|